Refine by
Precision Oncology Equipment & Supplies
12 equipment items found
Manufactured by:XILIS, Inc. based inDurham, NORTH CAROLINA (USA)
Xilis’ MicroOrganoSphereTM powers the only assay which can provide oncologists with accurate results of drug sensitivity on a patient’s own tumor within the clinical decision-making window - finally realizing the promise of precision medicine. Xilis is developing a panel of disease specific assays systematically testing the most important standard-of-care drugs within equipoise or ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
GPX4 neutralizes toxic free radicals at the lipid membrane, protecting cells from death by ferroptosis. BridgeBio is developing covalent inhibitors of GPX4 designed to induce ferroptosis in cancer cells. BridgeBio has entered into a strategic collaboration with Helsinn to co-develop and co-commercialize a potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) with ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
Infigratinib is an orally administered, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of FGFR-driven cancers. Multiple Phase 3 clinical trials are currently enrolling; please explore www.clinicaltrials.gov for more information. TRUSELTIQ™ (infigratinib) obtained accelerated approval by FDA, was conditionally approved by Health Canada and received ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
RAS is one of the most well-known oncogenic drivers, with approximately 30% of all cancers being driven by RAS mutations, including large proportions of lung, colorectal and pancreatic tumors. BridgeBio’s approach to RAS cancers encompasses multiple “shots on goal” that target both KRAS mutant tumors and those in which RAS activates PI3Ka. We believe two of our approaches have ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
BridgeBio is developing SHP2 inhibitors as potentially effective additions to the therapeutic arsenal for difficult-to-treat cancers. SHP2, encoded by the PTPN11 gene, links growth factor signaling with the downstream RAS/ERK/MAPK pathway to regulate cell growth and division. Over-activity of this pathway, often driven by distinct gene mutations, causes or contributes to many human cancers. ...
Manufactured by:Exscientia based inOxford, UNITED KINGDOM
In the landmark study, it was demonstrated for the first time that our functional precision-oncology platform can improve patient outcome in a prospective interventional ...
by:Pars Isotope Co based inTehran, IRAN
This unique action stems from its characteristic as a gamma emitter, allowing not only for therapeutic intervention but also for imaging and monitoring of treatment progress. Ideal for precision oncology, Lu-177-PSMA combines targeted therapeutic effectiveness with diagnostic capabilities, playing a crucial role in managing advanced prostate cancer cases by ...
by:NeoGenomics Laboratories based inFort Myers, FLORIDA (USA)
InVisionFirst®-Lung, a ctDNA NGS liquid biopsy testing 37 genes relevant to the care of patients with advanced NSCLC. Covered for Medicare and other private insurance NSCLC patients who meet specific clinical criteria in the United States. InVisionFirst-Lung® is available world-wide for both commercial and research use. ...
Manufactured by:Salutaris Medical Devices, Inc. (SMD) based inTucson, ARIZONA (USA)
SalutarisMD [SMD] is a clinical stage medical device company. SMD's BetaCurve is a globally-patented, 510(k)-cleared device designed to treat various ophthalmic diseases with precision beta radiotherapy, including PCV. The BetaCurve™ curves around the back of the eye to precisely deliver therapeutic beta radiation to the diseased area using a fiber optic light source for placement ...
Manufactured by:Kura Oncology, Inc. based inSan Diego, CALIFORNIA (USA)
With the advent of precision medicines that can target unique molecular or genetic features of a patient’s tumor, the field of oncology has a host of alternatives to one-size-fits-all treatments. This is a major advance over traditional chemotherapy, which can be as potent against healthy tissue as it is against cancer. Using tumor genomic profiling and ...
Manufactured by:Amoy Diagnostics Co., Ltd. based inXiamen, CHINA
Lung cancer is one of the most common malignant tumor, and 80~85% of lung cancers are non-small cell lung cancer (NSCLC). There are many driver mutations in NSCLC. The frequency of mutations in patients with NSCLC for the EGFR gene is 10~35%, for KRAS 15?25%, for BRAF1-4%, for NRAS is 1%, for HER2 2-4%, and for PIK3CA 1-3%. About 3-7% of NSCLC patients have gene fusion in ALK, 2% in ROS1, and 1% ...
Manufactured by:Thermo Scientific - LC/MS GC GC/MS based in, MASSACHUSETTS (USA)
Designed to make next-generation sequencing (NGS) accessible to clinical laboratories with all levels of sequencing expertise, the Ion Torrent Genexus Dx Integrated Sequencer delivers an effortless user experience while enabling regulatory ...